VEGF-C对胰腺癌淋巴结转移的作用机制及其与预后相关性的研究
|
摘要
胰腺癌是预后最为恶劣的消化系统恶性肿瘤之一,90%的患者就诊时已属进展期,治疗手段单一,手术切除率低,5年生存率不超过5%。而胰腺癌早期即可发生区域淋巴结转移,是影响患者预后的重要因素。因此,对胰腺癌淋巴结转移机制及干预手段的深入研究具有重要的意义。
VEGF-C基因是1996年被克隆定位于人染色体4q34上的一个新基因。近年来的大量研究结果显示,其与肿瘤淋巴结转移高度特异性相关。目前认为,VEGF-C通过结合淋巴管内皮细胞上表达的受体VEGFR-3促进肿瘤“淋巴管生成”是肿瘤淋巴结转移的关键机制之一。但实验研究证实,沉默VEGFR-3的表达以抑制肿瘤“淋巴管生成”对已转移至淋巴结的肿瘤细胞并无抑制作用。因此,对就诊时多已发生淋巴结转移的胰腺癌患者来说,抑制肿瘤“淋巴管生成”的效果可能并不乐观。
最近,有研究结果提示肿瘤细胞VEGF-C的异常表达与肿瘤细胞寄生部位的局部微环境关系密切。进一步通过免疫组织化学染色的方法,在乳腺癌原位种植瘤模型中发现存在部分转移至淋巴管内的乳腺癌细胞VEGF-C阳性表达增多的情况;而对人胰腺癌标本中也发现,转移至淋巴结的胰腺癌细胞VEGF-C染色阳性率明显高于原发灶的有趣现象。
那么,在淋巴结转移灶局部微环境的影响下,胰腺癌细胞VEGF-C表达是否存在器官差异性呢?如果存在,这种差异性对胰腺癌细胞淋巴结转移又发挥何种作用,能否为我们提供一个抑制胰腺癌细胞淋巴结转移的新思路呢?通过对VEGF-C在胰腺癌淋巴结转移中作用的进一步认识,其能否成为判断胰腺癌预后的一种辅助指标呢?
为此,我们进行了以下三个部分的研究。
第一部分VEGF-C在胰腺癌细胞种植瘤模型原位灶与淋巴结转移灶中表达的差异性
目的:
研究胰腺癌PANC-1细胞在原位种植瘤模型原位灶与淋巴结转移灶中VEGF-C表达的差异性。
方法:
建立胰腺癌PANC-1细胞原位种植瘤模型,原代分离培养原位灶与淋巴结转移灶中肿瘤细胞,通过RT-PCR、Western Blot、ELISA等方法检测其VEGF-C的表达情况。
结果:
胰腺癌PANC-1细胞原位种植瘤模型成瘤率100.0%,自发性淋巴结转移发生率为62.5%,自发性肝转移发生率为25.0%,未见肺转移。
将原代分离培养的原位灶与淋巴结转移灶中胰腺癌细胞分别命名为PANC-1-PRO和PANC-1-LN细胞。两细胞中VEGF-C基因mRNA表达水平分别为0.61±0.15与0.87±0.11,细胞中的VEGF-C蛋白表达水平分别为0.65±0.17与0.88±0.09,细胞培养液上清液中VEGF-C蛋白表达含量分别为(1403.67±128.15)pg/ml与(1682.37±156.73)pg/ml,PANC-1-LN细胞VEGF-C的表达水平均明显高于PANC-1-PRO细胞,差异有统计学意义(t=3.1255、2.9062、3.0782,P=0.0141、0.0197、0.0152)。
结论:
原位种植瘤模型自发性淋巴结转移灶中胰腺癌PANC-1细胞的VEGF-C表达水平显著高于原位灶中肿瘤细胞,胰腺癌细胞的VEGF-C表达存在器官差异性。
第二部分
VEGF-C特异性反义寡核苷酸对淋巴结转移灶胰腺癌细胞凋亡的影响
目的:
研究VEGF-C特异性反义寡核苷酸对原位灶与淋巴结转移灶中胰腺癌细胞凋亡的影响。
方法:
建立胰腺癌PANC-1细胞原位种植瘤模型,原代分离培养原位灶与淋巴结转移灶中肿瘤细胞(PANC-1-PRO和PANC-1-LN细胞),分为空白对照、错义寡核苷酸、反义寡核苷酸3个处理组。应用RT-PCR、Western Blot、ELISA、流式细胞术、TUNEL等方法检测VEGF-C反义寡核苷酸的体内外转染对其表达水平以及对胰腺癌细胞凋亡的影响。
结果:
体外转染后,反义组PANC-1-PRO和PANC-1-LN细胞中VEGF-C的mRNA、蛋白表达水平及细胞培养液上清液中蛋白表达含量均较空白、错义组显著降低(P<0.01)。而3组PANC-1-PRO和PANC-1-LN细胞中凋亡相关基因bcl-2的mRNA表达水平分别为0.67±0.12、0.69±0.14、0.61±0.11和0.56±0.16、0.59±0.18、0.27±0.17,仅PANC-1-LN细胞的反义组bcl-2表达水平较前2组明显下调(t=3.0428、3.1659,P=0.0124、0.0101)。PANC-1-PRO细胞转染后,3组的早期细胞凋亡率分别为(3.51±1.38)%、(4.79±2.16)%、(5.33±2.18)%,差异无统计学意义(t=1.7279、0.4310,P=0.1147、0.6756);而PANC-1-LN细胞3组早期细胞凋亡率分别为(2.83±1.01)%、(4.98±2.05)%、(13.22±2.17)%,反义组细胞凋亡率显著上升,差异有显著统计学意义(t=10.6329、6.7613,P=0.0000、0.0000)。
体内转染后,反义组种植瘤模型血清中VEGF-C蛋白含量较空白、错义组显著降低(P<0.05)。3组模型瘤体体积、淋巴结转移发生率及转移淋巴结数的差异均无统计学意义(P>0.05)。3组原位灶胰腺癌细胞凋亡率分别为(1.29±0.53)%、(1.98±0.77)%、(2.01±0.80)%,组间差异均无统计学意义(t=2.1221、0.0764,P=0.0522、0.9402);而3组淋巴结转移灶胰腺癌细胞平均凋亡率分别为(1.78±0.49)%、(1.96±0.68)%、(4.38±1.02)%,反义组细胞凋亡率显著上升,差异有显著统计学意义(t=6.4987、5.2301,P=0.0000、0.0001)。
结论:
抑制淋巴结转移灶中胰腺癌细胞VEGF-C的表达可促进淋巴结转移灶中胰腺癌细胞的凋亡,和bcl-2表达下调有关;但对原发灶胰腺癌细胞无明显影响。VEGF-C基因的作用机制也存在器官差异性,是胰腺癌淋巴结转移的机制之一。
第三部分
无法切除胰腺癌患者血清VEGF-C蛋白含量与预后相关性的研究
目的:
研究无法切除胰腺癌患者血清中VEGF-C蛋白含量与预后的关系。
方法:
选择华中科技大学同济医学院附属协和医院胰腺外科中心2004年12月～2005年8月间无法切除的局部晚期胰腺癌病例35例,记录入组时的KPS评分、CT资料的肿瘤最大直径及血清CA19-9值等相关指标。ELISA检测患者血清中VEGF-C蛋白含量,并选择10例健康者血清作为对照。应用Kaplan-Meier法计算生存率,并绘制生存曲线,Log-rank法检验不同变量间生存率的差异,Cox回归模型进行预后的单因素分析和多因素分析。
结果:
35例胰腺癌患者血清中VEGF-C蛋白含量平均值为(1309.23±542.05)pg/ml,10例对照者为(256.13±96.59)pg/ml,差异有统计学意义(P<0.05)。
将35例胰腺癌患者的年龄、肿瘤最大直径、肿瘤生长部位、KPS评分、血清CA19-9值及VEGF-C值等指标一起纳入Cox风险模型,进行预后单因素分析,发现KPS评分、血清CA19-9值及VEGF-C值均入选为无法切除的晚期胰腺癌患者预后影响因素(χ2=7.208、6.908、3.867,P=0.007、0.029、0.049)。
对上述筛选变量进行多因素Cox回归模型分析,引入标准为0.10、删除标准为0.11,采用后退法,发现最先退出模型的是CA19-9值(χ2=3.738,P=0.053),然后是VEGF-C(χ2=4.873,P=0.027),最后是KPS评分(χ2=5.274,P=0.022),。
比较KPS评分<70分与≥70分的两组病例预后,结果显示2组平均生存时间分别为6.60月与10.11月,1年累积生存率分别为21.43%与33.33%;取胰腺癌患者血清中VEGF-C蛋白含量中位数1280pg/ml为分界点,比较血清VEGF-C值≤1280pg/ml与>1280pg/ml的两组病例预后,结果显示2组平均生存时间分别为11.26月与6.29月,1年累积生存率分别为50.00%与5.88%;KPS评分及血清VEGF-C值的组间差异均有统计学意义(χ2=4.0400、9.4000,P=0.0443、0.0022)。而血清CA19-9值≤200U /ml与>200U/ml的两组病例,平均生存时间分别为9.99月与7.76月,1年累积生存率分别为37.50%与21.05%,差异无统计学意义(χ2=1.9100,P=0.1667)。
结论:
无法切除的局部晚期胰腺癌患者,其KPS评分和预后显著相关,可作为预后的独立影响因素;而血清中VEGF-C蛋白含量值与CA19-9值均和预后存在一定关系,可作为预后判断的辅助参考指标。
PartⅠThe different expression of VEGF-C on primary tumor and lymph node metastasis of nude mice with orthotopic implantation for the human pancreatic cancer cell
Objective:
To investigate the different expression of vascular endothelial growth factor C (VEGF-C) on pancreatic cancer cell PANC-1 derived from primary tumor and spontaneous lymph node metastasis.
Methods:
Establishment of the spontaneous lymph node metastasis model in nude mice with orthotopic implantation for the human pancreatic cancer cell line PANC-1. Then, isolate and culture the pancreatic cancer cell from primary tumor and spontaneous lymph node metastasis. The different expression of VEGF-C on pancreatic cancer cell was detected by RT-PCR, Western Blot, ELISA.
Results:
The rate of tumor take was 100.0%. The rate of the spontaneous lymph node metastasis was 62.5%. The rate of the spontaneous hepatic metastasis was 25.0%. Not to see lung metastasis.
The pancreatic cancer cell PANC-1 isolated from primary tumor and spontaneous lymph node metastasis were designated PANC-1-PRO and PANC-1-LN, separately. The mRNA levels of VEGF-C were 0.61±0.15 and 0.87±0.11 respectively; The protein levels of VEGF-C were 0.65±0.17 and 0.88±0.09 respectively inside 2 cells; Then the VEGF-C levels in culture supernatants were (1403.67±128.15) pg/ml and (1682.37±156.73) pg/ml. The levels of VEGF-C in PANC-1-LN cell were higher than PANC-1-PRO cell, the differentiation were statistical significance (t=3.1255、2.9062、3.0782,P=0.0141、0.0197、0.0152).
Conclusions:
The expressive level of VEGF-C on pancreatic cancer cell PANC-1 derived from spontaneous lymph node metastasis was higher than cell derived from primary tumor, the expression of VEGF-C on different organ was discrepancy.
PartⅡ
Effect on apoptosis of pancreatic cancer derived from lymph node metastasis with antisense oligonucleotide of VEGF-C
Objective:
To investigate the effect of VEGF-C antisense oligonucleotide on pancreatic cancer cell PANC-1 derived from primary tumor and spontaneous lymph node metastasis.
Methods:
Establishment of the spontaneous lymph node metastasis model in nude mice with orthotopic implantation for the human pancreatic cancer cell line PANC-1. Then, isolate and culture the pancreatic cancer cell from primary tumor and spontaneous lymph node metastasis (PANC-1-PRO and PANC-1-LN). The cells were randomized into 3 groups: Control group, scramble-sense oligonucleotide (SODN) group and antisense oligonucleotide (ASODN) group. The effect of transfection on the expressive VEGF-C and apoptosis of pancreatic cancer cells were detected by RT-PCR, Western Blot, ELISA, flow cytometer and TUNEL in vitro and vivo.
Results:
After treatment in vitro, the VEGF-C level of mRNA, protein and culture supernatants on ASODN group of PANC-1-PRO and PANC-1-LN were decreased than control group and SODN group (P<0.01). In 3 groups of PANC-1-PRO and PANC-1-LN, the mRNA levels of apoptosis related gene bcl-2 were 0.67±0.12, 0.69±0.14, 0.61±0.11 and 0.56±0.16, 0.59±0.18, 0.27±0.17 separately. Only ASODN group of PANC-1-LN was decreased significantly (t=3.0428、3.1659,P=0.0124、0.0101). The rates of early apoptosis were (3.51±1.38)%, (4.79±2.16)%, (5.33±2.18)% in PANC-1-PRO, the differentiation were not statistical significance (t=1.7279、0.4310,P=0.1147、0.6756); But the rates were (2.83±1.01)%, (4.98±2.05)%, (13.22±2.17)% in PANC-1-LN, ASODN group was elevated, the differentiation were statistical significance (t=10.6329、6.7613,P=0.0000、0.0000);
After treatment in vivo, the serum VEGF-C level of ASODN group were decreased than control group and SODN group in model(P<0.05). The volume of tumor, rates and parameter of lymph node metastasis all were not statistical differentiation (P>0.05). The rates of apoptosis were (1.29±0.53)%, (1.98±0.77)%, (2.01±0.80)% in 3 groups of primary tumor, the differentiation were not statistical significance (t=2.1221、0.0764,P=0.0522、0.9402); But in groups of lymph node metastasis, the rates of apoptosis were (1.78±0.49)%, (1.96±0.68)%, (4.38±1.02)% respectively, the rates of ASODN group was elevated, the differentiation were statistical significance (t=6.4987、5.2301,P=0.0000、0.0001).
Conclusions:
To inhibit the expression of VEGF-C on pancreatic cancer derived from lymph node metastasis can decreased the level of bcl-2, and promoted it to apoptosis, but no effect on pancreatic cancer derived from primary tumor. It is suggested that the effect of VEGF-C also have organic differentiation. It is mechanism of lymph node metastasis in pancreatic cancer.
PartⅢ
The correlation between the serum concentration of VEGF-C and prognosis in unrecetable pancreatic cancer
Objective:
To investigate the correlation between the serum concentration of VEGF-C and prognosis in unrecetable pancreatic cancer.
Methods:
In this study, select 35 unrecetable local advanced pancreatic cancer cases in Pancreatic Surgical Center of Union Hospital, Wuhan, China, from Dec. 2004 to Aug. 2005. We review karnofsky performance scale index (KPS), diameter of tumor and serum concentration of CA19-9. And the serum concentration of VEGF-C detected by ELISA, 10 health cases as to control. Survival rate and curves were calculated and drown by Kaplan-Meier. Survival rates in different groups were processed with Log-rank. Univariance and multiplevariance analysis were used to screen by Cox congression.
Results:
The mean serum concentration of VEGF-C was (1309.23±542.05) pg/ml, control group was (256.13±96.59) pg/ml, the differentiation were statistical significance (P<0.05).
The patient year, diameter of tumor, position of tumor, KPS, the serum concentration of VEGF-C and CA19-9were univariance analysed by Cox congression. KPS, the serum concentration of CA19-9 and VEGF-C were all correlated with prognosis in unrecetable pancreatic cancer (χ2=7.208、6.908、3.867,P=0.007、0.029、0.049).
In multiplevariance analysis by Cox congression (backward), SLE was 0.10, SLS was 0.11, the sequence of markers stepwise backward to model: Step 1 was VEGF-C (χ2=3.738,P=0.053), step 2 was VEGF-C (χ2=4.873,P=0.027), step 3 was KPS (χ2=5.274,P=0.022).
In groups of KPS <70 and≥70分, The median survival were 6.60 and 10.11 months, the survival rates of 1 year were 21.43% and 33.33% respectively. As the median of VEGF-C was 1280pg/ml, in groups of≤1280pg/ml and >1280pg/ml, the median survival were 11.26 and 6.29 months, the survival rates of 1 year were 50.00% and 5.88% respectively, the differentiation were statistical significance (χ2=4.0400、9.4000,P=0.0443、0.0022). But, in groups of CA19-9≤200U /ml and >200U/ml, the median survival were 9.99 and 7.76 months, the survival rates of 1 year were 37.50% and 21.05% respectively, the differentiation were not statistical significance (χ2=1.9100,P=0.1667). Conclusions:
KPS of the patients were independent factor of prognosis in unrecetable pancreatic cancer. The serum concentration of VEGF-C and CA19-9 were yet correlated with prognosis, and can used as aid marker for judgement of prognosis.
VEGF-C基因是1996年被克隆定位于人染色体4q34上的一个新基因。近年来的大量研究结果显示,其与肿瘤淋巴结转移高度特异性相关。目前认为,VEGF-C通过结合淋巴管内皮细胞上表达的受体VEGFR-3促进肿瘤“淋巴管生成”是肿瘤淋巴结转移的关键机制之一。但实验研究证实,沉默VEGFR-3的表达以抑制肿瘤“淋巴管生成”对已转移至淋巴结的肿瘤细胞并无抑制作用。因此,对就诊时多已发生淋巴结转移的胰腺癌患者来说,抑制肿瘤“淋巴管生成”的效果可能并不乐观。
最近,有研究结果提示肿瘤细胞VEGF-C的异常表达与肿瘤细胞寄生部位的局部微环境关系密切。进一步通过免疫组织化学染色的方法,在乳腺癌原位种植瘤模型中发现存在部分转移至淋巴管内的乳腺癌细胞VEGF-C阳性表达增多的情况;而对人胰腺癌标本中也发现,转移至淋巴结的胰腺癌细胞VEGF-C染色阳性率明显高于原发灶的有趣现象。
那么,在淋巴结转移灶局部微环境的影响下,胰腺癌细胞VEGF-C表达是否存在器官差异性呢?如果存在,这种差异性对胰腺癌细胞淋巴结转移又发挥何种作用,能否为我们提供一个抑制胰腺癌细胞淋巴结转移的新思路呢?通过对VEGF-C在胰腺癌淋巴结转移中作用的进一步认识,其能否成为判断胰腺癌预后的一种辅助指标呢?
为此,我们进行了以下三个部分的研究。
第一部分VEGF-C在胰腺癌细胞种植瘤模型原位灶与淋巴结转移灶中表达的差异性
目的:
研究胰腺癌PANC-1细胞在原位种植瘤模型原位灶与淋巴结转移灶中VEGF-C表达的差异性。
方法:
建立胰腺癌PANC-1细胞原位种植瘤模型,原代分离培养原位灶与淋巴结转移灶中肿瘤细胞,通过RT-PCR、Western Blot、ELISA等方法检测其VEGF-C的表达情况。
结果:
胰腺癌PANC-1细胞原位种植瘤模型成瘤率100.0%,自发性淋巴结转移发生率为62.5%,自发性肝转移发生率为25.0%,未见肺转移。
将原代分离培养的原位灶与淋巴结转移灶中胰腺癌细胞分别命名为PANC-1-PRO和PANC-1-LN细胞。两细胞中VEGF-C基因mRNA表达水平分别为0.61±0.15与0.87±0.11,细胞中的VEGF-C蛋白表达水平分别为0.65±0.17与0.88±0.09,细胞培养液上清液中VEGF-C蛋白表达含量分别为(1403.67±128.15)pg/ml与(1682.37±156.73)pg/ml,PANC-1-LN细胞VEGF-C的表达水平均明显高于PANC-1-PRO细胞,差异有统计学意义(t=3.1255、2.9062、3.0782,P=0.0141、0.0197、0.0152)。
结论:
原位种植瘤模型自发性淋巴结转移灶中胰腺癌PANC-1细胞的VEGF-C表达水平显著高于原位灶中肿瘤细胞,胰腺癌细胞的VEGF-C表达存在器官差异性。
第二部分
VEGF-C特异性反义寡核苷酸对淋巴结转移灶胰腺癌细胞凋亡的影响
目的:
研究VEGF-C特异性反义寡核苷酸对原位灶与淋巴结转移灶中胰腺癌细胞凋亡的影响。
方法:
建立胰腺癌PANC-1细胞原位种植瘤模型,原代分离培养原位灶与淋巴结转移灶中肿瘤细胞(PANC-1-PRO和PANC-1-LN细胞),分为空白对照、错义寡核苷酸、反义寡核苷酸3个处理组。应用RT-PCR、Western Blot、ELISA、流式细胞术、TUNEL等方法检测VEGF-C反义寡核苷酸的体内外转染对其表达水平以及对胰腺癌细胞凋亡的影响。
结果:
体外转染后,反义组PANC-1-PRO和PANC-1-LN细胞中VEGF-C的mRNA、蛋白表达水平及细胞培养液上清液中蛋白表达含量均较空白、错义组显著降低(P<0.01)。而3组PANC-1-PRO和PANC-1-LN细胞中凋亡相关基因bcl-2的mRNA表达水平分别为0.67±0.12、0.69±0.14、0.61±0.11和0.56±0.16、0.59±0.18、0.27±0.17,仅PANC-1-LN细胞的反义组bcl-2表达水平较前2组明显下调(t=3.0428、3.1659,P=0.0124、0.0101)。PANC-1-PRO细胞转染后,3组的早期细胞凋亡率分别为(3.51±1.38)%、(4.79±2.16)%、(5.33±2.18)%,差异无统计学意义(t=1.7279、0.4310,P=0.1147、0.6756);而PANC-1-LN细胞3组早期细胞凋亡率分别为(2.83±1.01)%、(4.98±2.05)%、(13.22±2.17)%,反义组细胞凋亡率显著上升,差异有显著统计学意义(t=10.6329、6.7613,P=0.0000、0.0000)。
体内转染后,反义组种植瘤模型血清中VEGF-C蛋白含量较空白、错义组显著降低(P<0.05)。3组模型瘤体体积、淋巴结转移发生率及转移淋巴结数的差异均无统计学意义(P>0.05)。3组原位灶胰腺癌细胞凋亡率分别为(1.29±0.53)%、(1.98±0.77)%、(2.01±0.80)%,组间差异均无统计学意义(t=2.1221、0.0764,P=0.0522、0.9402);而3组淋巴结转移灶胰腺癌细胞平均凋亡率分别为(1.78±0.49)%、(1.96±0.68)%、(4.38±1.02)%,反义组细胞凋亡率显著上升,差异有显著统计学意义(t=6.4987、5.2301,P=0.0000、0.0001)。
结论:
抑制淋巴结转移灶中胰腺癌细胞VEGF-C的表达可促进淋巴结转移灶中胰腺癌细胞的凋亡,和bcl-2表达下调有关;但对原发灶胰腺癌细胞无明显影响。VEGF-C基因的作用机制也存在器官差异性,是胰腺癌淋巴结转移的机制之一。
第三部分
无法切除胰腺癌患者血清VEGF-C蛋白含量与预后相关性的研究
目的:
研究无法切除胰腺癌患者血清中VEGF-C蛋白含量与预后的关系。
方法:
选择华中科技大学同济医学院附属协和医院胰腺外科中心2004年12月～2005年8月间无法切除的局部晚期胰腺癌病例35例,记录入组时的KPS评分、CT资料的肿瘤最大直径及血清CA19-9值等相关指标。ELISA检测患者血清中VEGF-C蛋白含量,并选择10例健康者血清作为对照。应用Kaplan-Meier法计算生存率,并绘制生存曲线,Log-rank法检验不同变量间生存率的差异,Cox回归模型进行预后的单因素分析和多因素分析。
结果:
35例胰腺癌患者血清中VEGF-C蛋白含量平均值为(1309.23±542.05)pg/ml,10例对照者为(256.13±96.59)pg/ml,差异有统计学意义(P<0.05)。
将35例胰腺癌患者的年龄、肿瘤最大直径、肿瘤生长部位、KPS评分、血清CA19-9值及VEGF-C值等指标一起纳入Cox风险模型,进行预后单因素分析,发现KPS评分、血清CA19-9值及VEGF-C值均入选为无法切除的晚期胰腺癌患者预后影响因素(χ2=7.208、6.908、3.867,P=0.007、0.029、0.049)。
对上述筛选变量进行多因素Cox回归模型分析,引入标准为0.10、删除标准为0.11,采用后退法,发现最先退出模型的是CA19-9值(χ2=3.738,P=0.053),然后是VEGF-C(χ2=4.873,P=0.027),最后是KPS评分(χ2=5.274,P=0.022),。
比较KPS评分<70分与≥70分的两组病例预后,结果显示2组平均生存时间分别为6.60月与10.11月,1年累积生存率分别为21.43%与33.33%;取胰腺癌患者血清中VEGF-C蛋白含量中位数1280pg/ml为分界点,比较血清VEGF-C值≤1280pg/ml与>1280pg/ml的两组病例预后,结果显示2组平均生存时间分别为11.26月与6.29月,1年累积生存率分别为50.00%与5.88%;KPS评分及血清VEGF-C值的组间差异均有统计学意义(χ2=4.0400、9.4000,P=0.0443、0.0022)。而血清CA19-9值≤200U /ml与>200U/ml的两组病例,平均生存时间分别为9.99月与7.76月,1年累积生存率分别为37.50%与21.05%,差异无统计学意义(χ2=1.9100,P=0.1667)。
结论:
无法切除的局部晚期胰腺癌患者,其KPS评分和预后显著相关,可作为预后的独立影响因素;而血清中VEGF-C蛋白含量值与CA19-9值均和预后存在一定关系,可作为预后判断的辅助参考指标。
PartⅠThe different expression of VEGF-C on primary tumor and lymph node metastasis of nude mice with orthotopic implantation for the human pancreatic cancer cell
Objective:
To investigate the different expression of vascular endothelial growth factor C (VEGF-C) on pancreatic cancer cell PANC-1 derived from primary tumor and spontaneous lymph node metastasis.
Methods:
Establishment of the spontaneous lymph node metastasis model in nude mice with orthotopic implantation for the human pancreatic cancer cell line PANC-1. Then, isolate and culture the pancreatic cancer cell from primary tumor and spontaneous lymph node metastasis. The different expression of VEGF-C on pancreatic cancer cell was detected by RT-PCR, Western Blot, ELISA.
Results:
The rate of tumor take was 100.0%. The rate of the spontaneous lymph node metastasis was 62.5%. The rate of the spontaneous hepatic metastasis was 25.0%. Not to see lung metastasis.
The pancreatic cancer cell PANC-1 isolated from primary tumor and spontaneous lymph node metastasis were designated PANC-1-PRO and PANC-1-LN, separately. The mRNA levels of VEGF-C were 0.61±0.15 and 0.87±0.11 respectively; The protein levels of VEGF-C were 0.65±0.17 and 0.88±0.09 respectively inside 2 cells; Then the VEGF-C levels in culture supernatants were (1403.67±128.15) pg/ml and (1682.37±156.73) pg/ml. The levels of VEGF-C in PANC-1-LN cell were higher than PANC-1-PRO cell, the differentiation were statistical significance (t=3.1255、2.9062、3.0782,P=0.0141、0.0197、0.0152).
Conclusions:
The expressive level of VEGF-C on pancreatic cancer cell PANC-1 derived from spontaneous lymph node metastasis was higher than cell derived from primary tumor, the expression of VEGF-C on different organ was discrepancy.
PartⅡ
Effect on apoptosis of pancreatic cancer derived from lymph node metastasis with antisense oligonucleotide of VEGF-C
Objective:
To investigate the effect of VEGF-C antisense oligonucleotide on pancreatic cancer cell PANC-1 derived from primary tumor and spontaneous lymph node metastasis.
Methods:
Establishment of the spontaneous lymph node metastasis model in nude mice with orthotopic implantation for the human pancreatic cancer cell line PANC-1. Then, isolate and culture the pancreatic cancer cell from primary tumor and spontaneous lymph node metastasis (PANC-1-PRO and PANC-1-LN). The cells were randomized into 3 groups: Control group, scramble-sense oligonucleotide (SODN) group and antisense oligonucleotide (ASODN) group. The effect of transfection on the expressive VEGF-C and apoptosis of pancreatic cancer cells were detected by RT-PCR, Western Blot, ELISA, flow cytometer and TUNEL in vitro and vivo.
Results:
After treatment in vitro, the VEGF-C level of mRNA, protein and culture supernatants on ASODN group of PANC-1-PRO and PANC-1-LN were decreased than control group and SODN group (P<0.01). In 3 groups of PANC-1-PRO and PANC-1-LN, the mRNA levels of apoptosis related gene bcl-2 were 0.67±0.12, 0.69±0.14, 0.61±0.11 and 0.56±0.16, 0.59±0.18, 0.27±0.17 separately. Only ASODN group of PANC-1-LN was decreased significantly (t=3.0428、3.1659,P=0.0124、0.0101). The rates of early apoptosis were (3.51±1.38)%, (4.79±2.16)%, (5.33±2.18)% in PANC-1-PRO, the differentiation were not statistical significance (t=1.7279、0.4310,P=0.1147、0.6756); But the rates were (2.83±1.01)%, (4.98±2.05)%, (13.22±2.17)% in PANC-1-LN, ASODN group was elevated, the differentiation were statistical significance (t=10.6329、6.7613,P=0.0000、0.0000);
After treatment in vivo, the serum VEGF-C level of ASODN group were decreased than control group and SODN group in model(P<0.05). The volume of tumor, rates and parameter of lymph node metastasis all were not statistical differentiation (P>0.05). The rates of apoptosis were (1.29±0.53)%, (1.98±0.77)%, (2.01±0.80)% in 3 groups of primary tumor, the differentiation were not statistical significance (t=2.1221、0.0764,P=0.0522、0.9402); But in groups of lymph node metastasis, the rates of apoptosis were (1.78±0.49)%, (1.96±0.68)%, (4.38±1.02)% respectively, the rates of ASODN group was elevated, the differentiation were statistical significance (t=6.4987、5.2301,P=0.0000、0.0001).
Conclusions:
To inhibit the expression of VEGF-C on pancreatic cancer derived from lymph node metastasis can decreased the level of bcl-2, and promoted it to apoptosis, but no effect on pancreatic cancer derived from primary tumor. It is suggested that the effect of VEGF-C also have organic differentiation. It is mechanism of lymph node metastasis in pancreatic cancer.
PartⅢ
The correlation between the serum concentration of VEGF-C and prognosis in unrecetable pancreatic cancer
Objective:
To investigate the correlation between the serum concentration of VEGF-C and prognosis in unrecetable pancreatic cancer.
Methods:
In this study, select 35 unrecetable local advanced pancreatic cancer cases in Pancreatic Surgical Center of Union Hospital, Wuhan, China, from Dec. 2004 to Aug. 2005. We review karnofsky performance scale index (KPS), diameter of tumor and serum concentration of CA19-9. And the serum concentration of VEGF-C detected by ELISA, 10 health cases as to control. Survival rate and curves were calculated and drown by Kaplan-Meier. Survival rates in different groups were processed with Log-rank. Univariance and multiplevariance analysis were used to screen by Cox congression.
Results:
The mean serum concentration of VEGF-C was (1309.23±542.05) pg/ml, control group was (256.13±96.59) pg/ml, the differentiation were statistical significance (P<0.05).
The patient year, diameter of tumor, position of tumor, KPS, the serum concentration of VEGF-C and CA19-9were univariance analysed by Cox congression. KPS, the serum concentration of CA19-9 and VEGF-C were all correlated with prognosis in unrecetable pancreatic cancer (χ2=7.208、6.908、3.867,P=0.007、0.029、0.049).
In multiplevariance analysis by Cox congression (backward), SLE was 0.10, SLS was 0.11, the sequence of markers stepwise backward to model: Step 1 was VEGF-C (χ2=3.738,P=0.053), step 2 was VEGF-C (χ2=4.873,P=0.027), step 3 was KPS (χ2=5.274,P=0.022).
In groups of KPS <70 and≥70分, The median survival were 6.60 and 10.11 months, the survival rates of 1 year were 21.43% and 33.33% respectively. As the median of VEGF-C was 1280pg/ml, in groups of≤1280pg/ml and >1280pg/ml, the median survival were 11.26 and 6.29 months, the survival rates of 1 year were 50.00% and 5.88% respectively, the differentiation were statistical significance (χ2=4.0400、9.4000,P=0.0443、0.0022). But, in groups of CA19-9≤200U /ml and >200U/ml, the median survival were 9.99 and 7.76 months, the survival rates of 1 year were 37.50% and 21.05% respectively, the differentiation were not statistical significance (χ2=1.9100,P=0.1667). Conclusions:
KPS of the patients were independent factor of prognosis in unrecetable pancreatic cancer. The serum concentration of VEGF-C and CA19-9 were yet correlated with prognosis, and can used as aid marker for judgement of prognosis.
引文
1. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100 313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg, 1999, 189: 1-7.
2.陈可欣,张思维,李连弟.中国胰腺癌死亡情况报告.中华流行病学杂志, 2003, 24: 520-522.
3. Yamamoto M, Ohashi O, Saitoh Y. Studies on TNM classification of carcinoma of the exocrine pancreas. Jpn J Cancer Chemother, 1998, 25: 143-149.
4. Berger AC, Watson JC, Rose EA, et al. The meastatic/examined lymph node ratio is an important progonostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg, 2004, 70 (3): 235-40.
5. Joukov V, Kalkkinen N, Alitalo K, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO, 1996, 15(2): 290-298.
6. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 15, 98(2): 413-423.
7. Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer, 2003, 89:426-430.
8. Yulong H, Iiro R, Katri P, et al. Vascular endothelial cell growth factor receptor
3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res, 2005, 65(11):4739-4746.
9. Krishnan J, Kirkin V, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713-722.
10. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer, 2004, 40: 1604-1609.
11. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated genetransfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
12. Terhi K, Mikala E, Marika J. K,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61:1786-1790.
13. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(15): 8413-8420.
1. Keleg S, Buchler P, Ludwig R, et al. Invasion and metastasis in pancreatic cancer. Mol Cancer, 2003, 2: 14-21.
2. Joukov V, Kalkkinen N, Alitalo K, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996, 15: 290-298.
3. Furudoi A, Tanaka S, Haruma K et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology, 2002, 62: 157-166.
4. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer. 2003, 15, 98(2): 413-23.
5. Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713- 722.
6. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor(VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer. 2004, 40: 1604-1609.
7. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
8. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(15): 8413-8420.
9. Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer, 2003, 89:426-430.
10. Tang RF, Itakura J, Aikawa T, et al. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas, 2001, 22(3): 285-292.
11. Joukov V, Sorsa, Alitalo K, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J, 1997, 16(13): 3898-3911.
12. Mandriota SJ, Jussila L, Alitalo K, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumourmetastasis. EMBO J, 2001, 20(4): 672-682.
13. Yulong H, Iiro R, Katri P, et al. Vascular endothelial cell growth factor receptor
3–mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res, 2005, 65(11): 4739-4746.
14. Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res, 2003, 63(8): 1920-1926.
15. Padera TP, Kadambi A, Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatic. Science, 2002, 296(5574): 1883-1886.
16. Karpanen T, Alitalo K. Lymphatic vessels as targets of tumor therapy. J Exp Med, 2001, 194(6): 37-40.
17. Sipos B, Kojima M, Tiemann K, et al. Lymphatic spread of ductal pancreaticadenocarcinoma is independent of lymphangiogenesis. J Pathol, 2005, 207(3): 301-312.
18. Scavellli C, Vacca A, Pietro GD, et al. Crosstalk between angiogenesis and lymphangiogenesis in tumor rogession. Leukemia, 2004, 18: 1054-1058.
19. Mandriota SJ, Jussila L, Jehsch M, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumour metastasis. EMBO J, 2001, 20(4): 672-682.
20. Terhi K, Mikala E, Marika JK,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61(1): 1786-1790.
21. Furodoi A, Tanaka S, Haruma K, et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology, 2002, 62(2): 157-166.
22. Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas, 2003, 26: E89-98.
23. Yao X, Hu JF, Daniels M, et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res, 2003, 9:2719-2726.
24. Bouvet M, Yang S, Nardin X, et al. Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin Exp Metastasis, 2000, 18: 213-218.
25. Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumor population. Nature, 1982, 297:593.
26. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev, 2002, 82: 673-700.
27. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related toperitumoral lymphangiogenesis. Am J Pathol, 2002, 161: 947-956.
1. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg, 1995, 82(1): 111-115.
2.王春友.胰腺癌根治性手术的反思及目前需要重新认识的几个问题.临床外科杂志, 2005,13(4):195-196.
3. Keleg S, Buchler P, Ludwig R, et al. Invasion and metastasis in pancreatic cancer. Mol Cancer, 2003, 2: 14-21.
4. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer. 2003, 15, 98(2): 413-23.
5. Yulong H, Iiro R, Katri P, et al. Vascular endothelial cell growth factor receptor
3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res, 2005, 65(11): 4739-4746.
6. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
7. Mandriota SJ, Jussila L, Jehsch M, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumour metastasis. EMBO J, 2001, 20(4): 672-682.
8. Terhi K, Mikala E, Marika JK,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61(1): 1786-1790.
9. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: anepidemiological study. Br J Surg. 1995,82(1):111-115.
10. Berger AC, Watson JC, Rose EA, et al. The meastatic/examined lymph node ratio is an important progonostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg, 2004, 70(3): 235-240.
11. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 98(2): 413-423.
12. Krishnan J, Kirkin V, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713- 722.
13. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer. 2004, 40: 1604-1609.
14. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
15. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(15): 8413–8420.
16. Li M, Yang H, Chai H, et al. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer, 2004, 101(10): 2341-2350.
17. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood, 2002, 99(3): 2179-2194.
18. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF-C autocrine loops. Int J Cancer, 2003, 104:603-610.
1. Frank B. Palliative care in pancreatic cancer. Cancer Cont, 2004, 11(1): 39-45.
2. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduoden Ectomies in the 1990s. Ann Surg, 1997, 266:248-260.
3. Nagakawa T, Konishi I, Higashino Y. The spread and prognosis of carcinoma in the region of the pancreatic head. Jpn J Surg, 1989, 19: 510-518.
4. Berger AC, Watson JC, Rose EA, et al. The meastatic/examined lymph node ratio is an important progonostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg, 2004, 70(3): 235-240.
5. Engelken FJ, Bettschart V, Rahman MQ, et al. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol, 2003, 29: 368-373.
6. Joukov V, Kalkkinen N, Alitalo K, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996, 15: 290-298.
7. Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer, 2003, 89:426-430.
8. Tamura M, Oda M, Matsumoto I, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol, 2004, 11(10): 928-933.
9. Mitsuhashi A, Suzuka K, Yamazawa K, et al. Cancer. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.2005, 103 (4): 724-730.
10. Berger AC, Meszoely IM, Ross EA, et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol, 2004, 11(7): 644-649.
11. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment andsurvival trends for 100313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg, 1999, 189: 1-7.
12.陈可欣,张思维,李连弟.中国胰腺癌死亡情况报告.中华流行病学杂志, 2003, 24:520-522.
13.王春友,熊炯炘,周峰,等. 49例胰腺癌血管浸润的术前评估和手术切除方法探讨.中华肝胆外科杂志, 2003, 9(11): 661-663.
14. Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer, 2005, 41(15): 2213-2236.
15.杨红,钱家鸣.胰腺癌相关肿瘤标志物研究进展.胰腺病学, 2006, 6(6): 375-376.
16. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 15, 98(2): 413-423.
17. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(5): 8413-8420.
1. Foster RS Jr. The biologic and clinical signicance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am, 1996, 5: 79-104.
2. Harrison JC, Dean PJ, El-Zeky F, et al. From dukes through jass pathological prognostic indicators in rectal cancer. Hum Pathol, 1994, 25:498-505.
3. Lymboussaki A, Achen MG, Stacker SA, et al. Growth factors regulating lymphatic vessels. Curr Top Microbiol Immunol, 2000, 251:75-82.
4. Kaipainen A, Korhonen J, Pajusola K, et al. The related FLT4, FLT1 and KDRreceptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med, 1993, 178:2077-2088.
5. Scavellli C, Vacca A, Pietro GD, et al. Crosstalk between angiogenesis and lymphangiogenesis in tumor rogession. Leukemia, 2004, 18:1054-1058.
6. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 2002, 1(3): 219-27.
7. Carr I. Lymphatic metastasis. Cancer Metastasis Rev, 1983, 2:307-317.
8. Van de Velde CJH, Carr I. Lymphatic invasion and metastasis. Experientia, 1977, 33: 837-884.
9. Liotta LA, Kohn E. Microenvironment of the tumour-host interface. Nature, 2001, 11: 375-379.
10. Barsky SH, Baker A, Siegal GP, et al. Use of anti-basement membrane antibodies to distinguish blood vessel capillaries from lymphatic capillaries. Am J Surg Pathol, 1983, 7(7): 667-677.
11. Soker S, Takashima S, Miao H, et al. Neuropilin is expressed by endothelial and tumor cells as isoform-specic receptor for vascular endothelial growth factor. Cell, 1998, 92:735-745.
12. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specic marker for lymphatic endothelium. Am J Pathol, 1999, 154:385-394.
13. Banerji S, Ni J, Wang SX, et al. LYVE-1, new homologue of the CD44 glycoprotein, is a lymph-speci.c receptor for hyaluronan. J Cell Biol, 1999, 144: 789-801.
14. Wigle JT, Oliver C. PROX-1 function is required for the development of the murine lymphatic system. Cell, 1999, 98:769-778.
15. Laakkonen P, Porkka K, Hoffman JA, et al. A tumor homing peptide with a targeting speci.city. Nat Med, 2002, 8:751-755.
16. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health anddisease. Cancer Cell, 2002, 1:219-227.
17. Schmid-Schonbein GW. Microlymphatics and lymph flow. Physiol Rev, 1990, 70: 987-1028.
18. Wigle JT, Oliver C. PROX-1 function is required for the development of the murine lymphatic system. Cell, 1999, 98:769-778.
19. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 1997, 276:1423-1425.
20. Eriksson U, Alitalo K. Structure, expression and receptor binding properties of novel vasculoendothelial growth factors. Curr Top Microbiol Immunol, 1999, 237:41-57.
21. Soker S, Takashima S, Miao H, et al. Neuropilin is expressed by endothelial and tumor cells as isoform-specic receptor for vascular endothelial growth factor. Cell, 1998, 92:735-745.
22. Dvorak HF, Brown LF, Detmar M, et al. Vascular perme- ability factor / vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 1995, 146(5): 1029-1039.
23. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med, 2002, 196(11): 1497-1506.
24. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 98(2): 413-423.
25. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, as a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996, 15:290-298.
26. Jeltsch M, Joukov V, Alitalo K, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 1997, 276(5317): 1423-1425.
27. Joukov V, Sorsa, Alitalo K, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J, 1997, 16(13): 3898-3911.
28. Oh SJ, Jeltsch MM, Alitalo K, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol, 1997, 188(1): 96-109.
29. Ristimaki A, Joukov V, Alitalo K, et al. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem, 1998, 273(14):8413-8418.
30. Byzova TV, Goldman CK, Jankau J, et al. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood, 2002, 99(12): 4434-4442.
31. Orlandini M, Oliviero S. In fibroblasts VEGF-D expression is induced by cell-cell contact mediated by cadherin-11. J Biol Chem, 2001, 276(9): 6576-6581.
32. George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia, 2001, 3(5):420-427.
33. Gluzman-Poltorak Z, Cohen T. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem, 2001, 276(22): 18688-18694.
34. Saaristo A, Alitalo K. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med, 2002, 196(6): 719-730.
35. Partanen TA, Arola J, Alitalo K. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J, 2000, 14(13): 2087-2096.
36. Makinen T, Jussila L, Alitalo K, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med, 2001, 7(2): 199-205.
37. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction. J Natl Cancer Inst, 2002, 94: 417-421.
38. Padera TP, Kadambi A, Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatic. Science, 2002, 296(5574): 1883-1886.
39. Beasley NJ, Prevo R. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res, 2002, 62(5): 1315-1320.
40. Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res, 2003, 63(8): 1920-1926.
41. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res, 2003, 9(1): 250-256.
42. Skobe M, Hawighorst T, Alitalo K, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med, 2001, 7(2):192-198.
43. Skobe M, Hamberg LM, Alitalo K, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol, 2001, 159(3): 893-903.
44. Mandriota SJ, Jussila L, Alitalo K, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumourmetastasis. EMBO J, 2001, 20(4): 672-682.
45. Karpanen T, Egeblad M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res, 2001, 61(5): 1786-1790.
46. Stacker SA, Caesar C. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med, 2001, 7(2):186-191.
47. He Y, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Nat Cancer Inst, 2002, 94(11):819-825.
48. Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713- 722.
49. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer, 2004, 40:1604-1609.
50. Tang RF, Itakura J, Aikawa T, et al. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas, 2001, 22(3): 285-292.
51.郭立霞,谢弘.肿瘤淋巴管生成.生命科学, 2003, 15(1): 36-38.
52. Terhi K, Mikala E, Marika JK,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61(1): 1786-1790.
53. Marchio S, Primo L, Pagano M, et al. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi’s sarcoma cells. JBC, 1999, 274(39): 27617-27622.
54. Masatsugu U, Yoshito Y, Koji K, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype m cervical carcinomas. Int J Cancer, 2002, 98(3): 335-343.
55.曲明阳,邢光明,冯秉安. VEGF-C反义寡核苷酸对乳腺癌细胞MDA-MB-435黏附、侵袭能力的影响.实用肿瘤杂志, 2005, 20(1): 21-24.
56. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood, 2002, 99(3): 2179-2194.
57. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF-C autocrine loops. Int J Cancer, 2003, 104:603-610.
2.陈可欣,张思维,李连弟.中国胰腺癌死亡情况报告.中华流行病学杂志, 2003, 24: 520-522.
3. Yamamoto M, Ohashi O, Saitoh Y. Studies on TNM classification of carcinoma of the exocrine pancreas. Jpn J Cancer Chemother, 1998, 25: 143-149.
4. Berger AC, Watson JC, Rose EA, et al. The meastatic/examined lymph node ratio is an important progonostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg, 2004, 70 (3): 235-40.
5. Joukov V, Kalkkinen N, Alitalo K, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO, 1996, 15(2): 290-298.
6. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 15, 98(2): 413-423.
7. Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer, 2003, 89:426-430.
8. Yulong H, Iiro R, Katri P, et al. Vascular endothelial cell growth factor receptor
3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res, 2005, 65(11):4739-4746.
9. Krishnan J, Kirkin V, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713-722.
10. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer, 2004, 40: 1604-1609.
11. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated genetransfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
12. Terhi K, Mikala E, Marika J. K,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61:1786-1790.
13. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(15): 8413-8420.
1. Keleg S, Buchler P, Ludwig R, et al. Invasion and metastasis in pancreatic cancer. Mol Cancer, 2003, 2: 14-21.
2. Joukov V, Kalkkinen N, Alitalo K, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996, 15: 290-298.
3. Furudoi A, Tanaka S, Haruma K et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology, 2002, 62: 157-166.
4. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer. 2003, 15, 98(2): 413-23.
5. Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713- 722.
6. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor(VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer. 2004, 40: 1604-1609.
7. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
8. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(15): 8413-8420.
9. Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer, 2003, 89:426-430.
10. Tang RF, Itakura J, Aikawa T, et al. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas, 2001, 22(3): 285-292.
11. Joukov V, Sorsa, Alitalo K, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J, 1997, 16(13): 3898-3911.
12. Mandriota SJ, Jussila L, Alitalo K, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumourmetastasis. EMBO J, 2001, 20(4): 672-682.
13. Yulong H, Iiro R, Katri P, et al. Vascular endothelial cell growth factor receptor
3–mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res, 2005, 65(11): 4739-4746.
14. Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res, 2003, 63(8): 1920-1926.
15. Padera TP, Kadambi A, Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatic. Science, 2002, 296(5574): 1883-1886.
16. Karpanen T, Alitalo K. Lymphatic vessels as targets of tumor therapy. J Exp Med, 2001, 194(6): 37-40.
17. Sipos B, Kojima M, Tiemann K, et al. Lymphatic spread of ductal pancreaticadenocarcinoma is independent of lymphangiogenesis. J Pathol, 2005, 207(3): 301-312.
18. Scavellli C, Vacca A, Pietro GD, et al. Crosstalk between angiogenesis and lymphangiogenesis in tumor rogession. Leukemia, 2004, 18: 1054-1058.
19. Mandriota SJ, Jussila L, Jehsch M, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumour metastasis. EMBO J, 2001, 20(4): 672-682.
20. Terhi K, Mikala E, Marika JK,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61(1): 1786-1790.
21. Furodoi A, Tanaka S, Haruma K, et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology, 2002, 62(2): 157-166.
22. Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas, 2003, 26: E89-98.
23. Yao X, Hu JF, Daniels M, et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res, 2003, 9:2719-2726.
24. Bouvet M, Yang S, Nardin X, et al. Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin Exp Metastasis, 2000, 18: 213-218.
25. Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumor population. Nature, 1982, 297:593.
26. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev, 2002, 82: 673-700.
27. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related toperitumoral lymphangiogenesis. Am J Pathol, 2002, 161: 947-956.
1. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg, 1995, 82(1): 111-115.
2.王春友.胰腺癌根治性手术的反思及目前需要重新认识的几个问题.临床外科杂志, 2005,13(4):195-196.
3. Keleg S, Buchler P, Ludwig R, et al. Invasion and metastasis in pancreatic cancer. Mol Cancer, 2003, 2: 14-21.
4. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer. 2003, 15, 98(2): 413-23.
5. Yulong H, Iiro R, Katri P, et al. Vascular endothelial cell growth factor receptor
3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res, 2005, 65(11): 4739-4746.
6. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
7. Mandriota SJ, Jussila L, Jehsch M, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumour metastasis. EMBO J, 2001, 20(4): 672-682.
8. Terhi K, Mikala E, Marika JK,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61(1): 1786-1790.
9. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: anepidemiological study. Br J Surg. 1995,82(1):111-115.
10. Berger AC, Watson JC, Rose EA, et al. The meastatic/examined lymph node ratio is an important progonostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg, 2004, 70(3): 235-240.
11. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 98(2): 413-423.
12. Krishnan J, Kirkin V, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713- 722.
13. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer. 2004, 40: 1604-1609.
14. Lin J, Lalani AS, Harding TC, et al. Inhibition of lymphogenous metastasis using adeno associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res, 2005, 65(15): 6901-6909.
15. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(15): 8413–8420.
16. Li M, Yang H, Chai H, et al. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer, 2004, 101(10): 2341-2350.
17. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood, 2002, 99(3): 2179-2194.
18. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF-C autocrine loops. Int J Cancer, 2003, 104:603-610.
1. Frank B. Palliative care in pancreatic cancer. Cancer Cont, 2004, 11(1): 39-45.
2. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduoden Ectomies in the 1990s. Ann Surg, 1997, 266:248-260.
3. Nagakawa T, Konishi I, Higashino Y. The spread and prognosis of carcinoma in the region of the pancreatic head. Jpn J Surg, 1989, 19: 510-518.
4. Berger AC, Watson JC, Rose EA, et al. The meastatic/examined lymph node ratio is an important progonostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg, 2004, 70(3): 235-240.
5. Engelken FJ, Bettschart V, Rahman MQ, et al. Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol, 2003, 29: 368-373.
6. Joukov V, Kalkkinen N, Alitalo K, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996, 15: 290-298.
7. Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer, 2003, 89:426-430.
8. Tamura M, Oda M, Matsumoto I, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol, 2004, 11(10): 928-933.
9. Mitsuhashi A, Suzuka K, Yamazawa K, et al. Cancer. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.2005, 103 (4): 724-730.
10. Berger AC, Meszoely IM, Ross EA, et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol, 2004, 11(7): 644-649.
11. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment andsurvival trends for 100313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg, 1999, 189: 1-7.
12.陈可欣,张思维,李连弟.中国胰腺癌死亡情况报告.中华流行病学杂志, 2003, 24:520-522.
13.王春友,熊炯炘,周峰,等. 49例胰腺癌血管浸润的术前评估和手术切除方法探讨.中华肝胆外科杂志, 2003, 9(11): 661-663.
14. Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer, 2005, 41(15): 2213-2236.
15.杨红,钱家鸣.胰腺癌相关肿瘤标志物研究进展.胰腺病学, 2006, 6(6): 375-376.
16. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 15, 98(2): 413-423.
17. Hiroshi K, Sonshin T, Kousei M, et al. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: Its relationship to lymph node metastasis. Clinical Cancer Research, 2004, 10(5): 8413-8420.
1. Foster RS Jr. The biologic and clinical signicance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am, 1996, 5: 79-104.
2. Harrison JC, Dean PJ, El-Zeky F, et al. From dukes through jass pathological prognostic indicators in rectal cancer. Hum Pathol, 1994, 25:498-505.
3. Lymboussaki A, Achen MG, Stacker SA, et al. Growth factors regulating lymphatic vessels. Curr Top Microbiol Immunol, 2000, 251:75-82.
4. Kaipainen A, Korhonen J, Pajusola K, et al. The related FLT4, FLT1 and KDRreceptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med, 1993, 178:2077-2088.
5. Scavellli C, Vacca A, Pietro GD, et al. Crosstalk between angiogenesis and lymphangiogenesis in tumor rogession. Leukemia, 2004, 18:1054-1058.
6. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 2002, 1(3): 219-27.
7. Carr I. Lymphatic metastasis. Cancer Metastasis Rev, 1983, 2:307-317.
8. Van de Velde CJH, Carr I. Lymphatic invasion and metastasis. Experientia, 1977, 33: 837-884.
9. Liotta LA, Kohn E. Microenvironment of the tumour-host interface. Nature, 2001, 11: 375-379.
10. Barsky SH, Baker A, Siegal GP, et al. Use of anti-basement membrane antibodies to distinguish blood vessel capillaries from lymphatic capillaries. Am J Surg Pathol, 1983, 7(7): 667-677.
11. Soker S, Takashima S, Miao H, et al. Neuropilin is expressed by endothelial and tumor cells as isoform-specic receptor for vascular endothelial growth factor. Cell, 1998, 92:735-745.
12. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specic marker for lymphatic endothelium. Am J Pathol, 1999, 154:385-394.
13. Banerji S, Ni J, Wang SX, et al. LYVE-1, new homologue of the CD44 glycoprotein, is a lymph-speci.c receptor for hyaluronan. J Cell Biol, 1999, 144: 789-801.
14. Wigle JT, Oliver C. PROX-1 function is required for the development of the murine lymphatic system. Cell, 1999, 98:769-778.
15. Laakkonen P, Porkka K, Hoffman JA, et al. A tumor homing peptide with a targeting speci.city. Nat Med, 2002, 8:751-755.
16. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health anddisease. Cancer Cell, 2002, 1:219-227.
17. Schmid-Schonbein GW. Microlymphatics and lymph flow. Physiol Rev, 1990, 70: 987-1028.
18. Wigle JT, Oliver C. PROX-1 function is required for the development of the murine lymphatic system. Cell, 1999, 98:769-778.
19. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 1997, 276:1423-1425.
20. Eriksson U, Alitalo K. Structure, expression and receptor binding properties of novel vasculoendothelial growth factors. Curr Top Microbiol Immunol, 1999, 237:41-57.
21. Soker S, Takashima S, Miao H, et al. Neuropilin is expressed by endothelial and tumor cells as isoform-specic receptor for vascular endothelial growth factor. Cell, 1998, 92:735-745.
22. Dvorak HF, Brown LF, Detmar M, et al. Vascular perme- ability factor / vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 1995, 146(5): 1029-1039.
23. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med, 2002, 196(11): 1497-1506.
24. Nathanson. Insights into the mechanisms of lymph node metastasis. Cancer, 2003, 98(2): 413-423.
25. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, as a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996, 15:290-298.
26. Jeltsch M, Joukov V, Alitalo K, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science, 1997, 276(5317): 1423-1425.
27. Joukov V, Sorsa, Alitalo K, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J, 1997, 16(13): 3898-3911.
28. Oh SJ, Jeltsch MM, Alitalo K, et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol, 1997, 188(1): 96-109.
29. Ristimaki A, Joukov V, Alitalo K, et al. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem, 1998, 273(14):8413-8418.
30. Byzova TV, Goldman CK, Jankau J, et al. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood, 2002, 99(12): 4434-4442.
31. Orlandini M, Oliviero S. In fibroblasts VEGF-D expression is induced by cell-cell contact mediated by cadherin-11. J Biol Chem, 2001, 276(9): 6576-6581.
32. George ML, Tutton MG, Janssen F, et al. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia, 2001, 3(5):420-427.
33. Gluzman-Poltorak Z, Cohen T. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem, 2001, 276(22): 18688-18694.
34. Saaristo A, Alitalo K. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med, 2002, 196(6): 719-730.
35. Partanen TA, Arola J, Alitalo K. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J, 2000, 14(13): 2087-2096.
36. Makinen T, Jussila L, Alitalo K, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med, 2001, 7(2): 199-205.
37. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction. J Natl Cancer Inst, 2002, 94: 417-421.
38. Padera TP, Kadambi A, Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatic. Science, 2002, 296(5574): 1883-1886.
39. Beasley NJ, Prevo R. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res, 2002, 62(5): 1315-1320.
40. Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res, 2003, 63(8): 1920-1926.
41. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res, 2003, 9(1): 250-256.
42. Skobe M, Hawighorst T, Alitalo K, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med, 2001, 7(2):192-198.
43. Skobe M, Hamberg LM, Alitalo K, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol, 2001, 159(3): 893-903.
44. Mandriota SJ, Jussila L, Alitalo K, et al. Vascular endothelial growth factor-C mediated lymphangiogenesis promotes tumourmetastasis. EMBO J, 2001, 20(4): 672-682.
45. Karpanen T, Egeblad M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res, 2001, 61(5): 1786-1790.
46. Stacker SA, Caesar C. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med, 2001, 7(2):186-191.
47. He Y, Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Nat Cancer Inst, 2002, 94(11):819-825.
48. Krishnan J, Kirkin V, Steffen A, et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 2003, 63(3): 713- 722.
49. Seiji O, Yasuhiko K, Shinji T, et al. Regulation of vascular endothelial growth factor (VEGF)-C and VEGF-D expression by the organ microenvironment in human colon carcinoma. Euro J Cancer, 2004, 40:1604-1609.
50. Tang RF, Itakura J, Aikawa T, et al. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas, 2001, 22(3): 285-292.
51.郭立霞,谢弘.肿瘤淋巴管生成.生命科学, 2003, 15(1): 36-38.
52. Terhi K, Mikala E, Marika JK,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cance Res, 2001, 61(1): 1786-1790.
53. Marchio S, Primo L, Pagano M, et al. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi’s sarcoma cells. JBC, 1999, 274(39): 27617-27622.
54. Masatsugu U, Yoshito Y, Koji K, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype m cervical carcinomas. Int J Cancer, 2002, 98(3): 335-343.
55.曲明阳,邢光明,冯秉安. VEGF-C反义寡核苷酸对乳腺癌细胞MDA-MB-435黏附、侵袭能力的影响.实用肿瘤杂志, 2005, 20(1): 21-24.
56. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood, 2002, 99(3): 2179-2194.
57. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF-C autocrine loops. Int J Cancer, 2003, 104:603-610.